Form 4: Cadrenal Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Glynn Wilson, a Director of Cadrenal Therapeutics, Inc., received 75,000 shares of common stock on October 9, 2026.
Summary
- Grant/award: acquired 75,000 Stock Option on October 9, 2026; holds 75,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Glynn Wilson — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-09 | Grant/award | Stock Option | 75,000 | — | — | 75,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-09 | Grant/award (75,000 shares) |
Keywords
insider transaction, Form 4, CVKD, Cadrenal Therapeutics, Inc., neutral, Glynn Wilson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.